These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29689379)

  • 21. Should minimal residual disease guide therapy in AML?
    Paietta E
    Best Pract Res Clin Haematol; 2015; 28(2-3):98-105. PubMed ID: 26590765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
    Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
    Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Universal monitoring of minimal residual disease in acute myeloid leukemia.
    Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
    JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
    Xiao W; Petrova-Drus K; Roshal M
    Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.
    Manara E; Basso G; Zampini M; Buldini B; Tregnago C; Rondelli R; Masetti R; Bisio V; Frison M; Polato K; Cazzaniga G; Menna G; Fagioli F; Merli P; Biondi A; Pession A; Locatelli F; Pigazzi M
    Leukemia; 2017 Jan; 31(1):18-25. PubMed ID: 27416911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical value of molecular MRD monitoring by next-generation sequencing in patients with
    Shumilov E; Flach J; Joncourt R; Porret N; Wiedemann G; Novak U; Gfeller E; Jeker B; Amstutz U; Pabst T; Bacher U
    Leuk Lymphoma; 2019 Oct; 60(10):2588-2590. PubMed ID: 30998101
    [No Abstract]   [Full Text] [Related]  

  • 29. Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
    Zaliova M; Zuna J; Winkowska L; Janotova I; Skorepova J; Lukes J; Meyer C; Marschalek R; Novak Z; Domansky J; Stary J; Sramkova L; Trka J
    Leukemia; 2024 Jan; 38(1):21-30. PubMed ID: 38001170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.
    Sakamoto Y; Mariya Y; Sasaki S; Teshiromori R; Oshikiri T; Segawa M; Ogura K; Akagi T; Kubo K; Kaimori M; Funato T
    Tohoku J Exp Med; 2009 Oct; 219(2):169-76. PubMed ID: 19776535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges.
    Álvarez N; Martín A; Dorado S; Colmenares R; Rufián L; Rodríguez M; Giménez A; Carneros L; Sanchez R; Carreño G; Rapado I; Heredia Y; Martínez-López J; Barrio S; Ayala R
    Front Immunol; 2024; 15():1252258. PubMed ID: 38938565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
    Chen X; Wood BL
    Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.
    Maurer-Granofszky M; Kohrer S; Fischer S; Schumich A; Nebral K; Larghero P; Meyer C; Mecklenbrauker A; Muhlegger N; Marschalek R; Haas OA; Panzer-Grumayer R; Dworzak MN
    Haematologica; 2024 Mar; 109(3):740-750. PubMed ID: 37345487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
    Ehinger M; Pettersson L
    APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
    Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
    Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia.
    Steinbach D; Bader P; Willasch A; Bartholomae S; Debatin KM; Zimmermann M; Creutzig U; Reinhardt D; Gruhn B
    Clin Cancer Res; 2015 Mar; 21(6):1353-9. PubMed ID: 25501127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.